NCT06083857 2026-03-11
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
10 trialsNCT05117931 2026-02-17
A Study of Amivantamab in People With Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07392658 2026-02-06
AMICUTE
Fondazione Ricerca Traslazionale
Phase 2 Recruiting
NCT05845671 2026-01-14
Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations
University of Colorado, Denver
Phase 1/2 Active not recruiting
NCT04965090 2025-12-18
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05299125 2025-10-01
AMIGO-1
Latin American Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06632236 2025-04-25
5G-EMERALD
Institute of Cancer Research, United Kingdom
Phase 1 Recruiting
NCT05074940 2025-04-10
Amivantamab in Adenoid Cystic Carcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT06855849 2025-03-04
An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.
Yonsei University
Phase 2 Not yet recruiting
NCT03767075 2024-04-25
BoB
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting